Kornimate/medical-research-clean huggingface dataset:
cryotherapy for the prevention of taxane-induced sensory neuropathy of the hands and feet in breast cancer patients

Conditions: Breast Carcinoma

Summary: this clinical trial investigates the effect and tolerability of cryotherapy and to evaluate whether they can prevent or improve taxane-induced sensory peripheral neuropathy in breast cancer patients. cryosurgery, also known as cryoablation or cryotherapy, kills tumor cells by freezing them. patients receiving cryotherapy during infusion of taxane therapy may have lower incidence of peripheral neuropathy, better physical function, and higher quality of life as compared to patients previously reported in literature.

primary objective: i. to investigate the efficacy and tolerability of cryotherapy (elasto gel frozen mittens and foot wraps) and to evaluate whether they can prevent or ameliorate taxane-induced sensory peripheral neuropathy. outline: patients wear elasto gel therapy mittens and foot wraps on both hands and feet 15 minutes prior to each infusion, during the entire infusion, and for 15 minutes after the completion of each infusion during their three months of treatment.

Eligibility criteria:
inclusion criteria: * patients \>= 18 years of age with a diagnosis of breast cancer * patients receiving 12-18 weeks of chemotherapy with a taxane-based regimen (4 cycles of weekly x 3 paclitaxel or 4-6 cycles of docetaxel every 3 weeks) * absence of sensory peripheral neuropathy, skin or nail disorders at the start of treatment * eastern cooperative oncology group (ecog) performance status of 0 to 2 * ability to complete questionnaires by themselves or with assistance * ability to give signed informed consent exclusion criteria: * history of prior sensory/motor peripheral neuropathy from any cause * history of prior raynaud's phenomenon * history of cryoglobulinemia * active peripheral vascular disease * cold intolerance * prior exposure to neurotoxic chemotherapy in the last 10 years * hand-foot syndrome * tumor metastasis in bone, soft tissue, or skin of the hands or feet * absence of one or more fingers or toes * prior exposure to taxane chemotherapy
a study of the safety, efficacy, and pharmacokinetics of tiragolumab in combination with atezolizumab and chemotherapy in participants with triple-negative breast cancer

Conditions: Triple-Negative Breast Cancer

Summary: the purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of tiragolumab in combination with atezolizumab and chemotherapy in participants with metastatic and early triple-negative breast cancer (tnbc).


Eligibility criteria:
inclusion criteria cohort a: * metastatic or locally advanced unresectable, histologically documented tnbc characterized by absence of human epidermal growth factor 2 (her2), estrogen receptor (er), and progesterone receptor (pr) expression * only patients with metastatic tnbc tumors that are centrally tested and found to be programmed death-ligand 1 (pd-l1) positive will be enrolled * no prior chemotherapy or targeted systemic therapy for inoperable locally advanced or metastatic tnbc * eastern cooperative oncology group performance status of 0 or 1 * measurable disease, as assessed by the investigator according to recist v1.1 * adequate hematologic and end-organ function cohort b: * eastern cooperative oncology group (ecog) performance status of 0 or 1 * histologically documented tnbc (negative her2, er, and pr status) * confirmed tumor pd-l1 evaluation as documented through central testing of a representative tumor tissue specimen * primary breast tumor size of greater than (\>) 2 centimeters (cm) by at least one radiographic or clinical measurement * stage at presentation: ct2-ct4, cn0-cn3, cm0 * baseline left ventricular ejection fraction (lvef) greater than or equal to (\>/=) 53 percent (%) measured by echocardiogram (echo) or multiple-gated acquisition (muga) scans * adequate hematologic and end-organ function exclusion criteria cohort a: * formalin-fixed, paraffin-embedded (ffpe) tumor tissue that is pd-l1 negative, as determined on the sp142 pd-l1 immunohistochemistry assay, with positivity defined as immune cells greater than or equal to (\>/=) 1% * spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for \>2 weeks prior to initiation of study treatment * known central nervous system (cns) disease, except for treated asymptomatic cns metastases * leptomeningeal disease cohort b: * history of invasive breast cancer * stage iv (metastatic) breast cancer * prior systemic therapy for treatment and prevention of breast cancer * previous therapy with anthracyclines, platinum, or taxanes for any malignancy * synchronous, bilateral invasive breast cancer * cardiopulmonary dysfunction
effectiveness study of different local anesthetic mixtures

Conditions: Pain

Summary: purpose and background the purpose of this research study is to investigate the benefits of mixing lidocaine and bupivacaine for numbing the skin. lidocaine and bupivacaine are two commonly used medications to numb the skin for minor procedures. lidocaine has a faster onset. bupivacaine has a longer duration. they are often combined with epinephrine to increase the length of action. these medications are used to control pain at the time of the operation and to decrease discomfort immediately afterward. participating in the study involves injection of local anesthetic containing lidocaine, bupivacaine, and lidocaine and bupivacain with epinephrine at 4 sites on the forearm. your participation will potentially improve the administration of these medications in persons undergoing a variety of procedures. you will be one of approximately 25 healthy volunteer subjects in this research study.

procedures during your participation the following procedures will be completed: * you will be asked to read over and sign this consent form, if you choose to participate * you will be asked demographic information and your medical history will be obtained * if you are eligible to participate, the palm side of your forearm will be marked for the location of the treatments * four small injections will be made into the palm side of your forearms with the local anesthetic mixtures (you will not know which injection is used at each of the four injection sites) * a small needle will be used for pinprick sensation to determine when numbness begins and ends length of study and number of visits this study begins at the time the medications are injected and is completed when sensation has completely returned. the study will last between 6 and 12 hours. during this time, you may perform low intensity tasks including reading, typing, and writing. you must remain in the study location as the sites will frequently be examined. exclusions you should not participate in this study if any of the following apply to you: * you are pregnant * you have an allergy to lidocaine or bupivacaine * you have a history of heart disease (including a prior heart attack, heart dysfunction, or heart failure) there may be other criteria that you have to meet to be eligible for this study. the study team can discuss these with you to determine whether you qualify. discomfort and risks risks associated with the injections include temporary discomfort at the injection site and possible infection. it is also possible that you have an allergic reaction or side effect to the medications that are being used. benefits there is no direct benefit to you for participating in this study. your participation will potentially improve the administration of these medications in persons undergoing a variety of procedures.

Eligibility criteria:
inclusion criteria: * age: 18-60 exclusion criteria: * pregnancy * allergy to local anesthetics * history of heart disease or diabetes
association of body fluid distribution with obstructive sleep apnea in pregnant women with body mass index ≥ 40 kg/m2

Conditions: Apnea, Obstructive Sleep; Obesity

Summary: obstructive sleep apnea (osa) is a common and underdiagnosed condition in obese pregnant women with serious and life-threatening complications to the mother and baby. the investiators propose that a non-invasive method may be used to detect patients at risk of osa, giving these women access to the necessary treatment to treat this condition. the method is a estimation of body water, which has been shown to be linked to osa in the non-pregnant population. body water is estimated by applying surface electrodes to a participant who is lying down by measuring bioimpedance through body tissues by applying a tiny current between the electrodes. the electrical stimulation is not felt by the participant and has no negative effects on mother or baby.

it is already established that the increasingly prevalent condition of obesity is linked to osa in pregnancy. obesity is increasingly prevalent this study will evaluate a novel method of screening for osa in the obese pregnant population, thereby treating this condition reducing the ill effects to mother and fetus. this will be a prospective observational cohort study. eligible participants will be approached for consent during their third-trimester antenatal all-day clinic visit. body water will be measured by connecting electrodes to participants hands, feet and neck whilst lying supine for approximately 15 minutes. data on patient demographics, bmi, medical conditions, water body composition and indicators of osa (breathing pattern and oxygen levels during sleep) will be collected, as well as data from patients' sleep tests as ordered by their physician.

Eligibility criteria:
inclusion criteria: * participants who give written informed consent * pregnant women in the third trimester of pregnancy * grade iii obesity * patients who have prior diagnosis of osa within the last one year, and non-compliant to treatment such as continuous positive airway pressure (cpap), or dental appliance * patients suspected to have osa based on screening questionnaire (see page 2, osa-diagnostic tools for further details) exclusion criteria: * fluid overload states including renal disease, liver disease and congestive heart failure * prior history of vascular surgery in the lower limbs such as varicose vein surgery, vascular by-pass surgery or evidence of venous efficiency. * patients with metal implants in lower limbs or spine, due to possible interference with the leg impedance signals. 58 * participants with diagnosed osa treated with continuous positive airway pressure (cpap). * patients requiring urgent sleep physician referral (within four weeks) due to serious medical conditions or safety critical-occupations according to the 2011 canadian thoracic society (cts) guideline 59 e.g. unstable ischemic heart disease, recent cerebrovascular disease. * implantable cardiac devices

Keywords: pregnancy
the effect of five-toed socks on postural control among active individuals who have chronic ankle instabilities

Conditions: Ankle Sprain

Summary: lateral ankle sprain (las) is one of the most common injuries in sports. there is a unique style of socks that have become popular in japan among athletes that could also improve postural control. the purpose of the study is to determine the effectiveness of five-toed socks on dynamic postural control in individuals with and without chronic ankle instability.

lateral ankle sprain (las) is one of the most common injuries in sports. ankle braces and orthotic insoles also have been shown to influence the neuromuscular control system by enhancing the proprioceptive and cutaneous afferent inputs to the central nerve system; thereby improving postural control. there is a unique style of socks that have become popular in japan among athletes that could also improve postural control by enhancing cutaneous afferent inputs from the plantar surface of the foot and toes. the purpose of the study is to determine the effectiveness of five-toed socks on dynamic postural control in individuals with and without chronic ankle instability.

Eligibility criteria:
inclusion criteria: * member of university community * all subjects will be physically active (at least 30 minutes of sustained exercise 3 times/week exclusion criteria: * history of: knee or hip musculoskeletal injury or surgery * history of: fracture or dislocation of the testing ankle or leg * neurological problems * vestibular disorders or concussions within the last 6 months
dexmedetomidine, ozone and dexamethasone local injection in carpal tunnel syndrome for pain relief

Conditions: Carpal Tunnel; Dexmedetomidine; Ozone; Dexamethasone

Summary: the aim of the present study is to compare the analgesic efficacy of dexmedetomidine, ozone and dexamethasone regional injection in carpal tunnel syndrome.

carpal tunnel syndrome (cts) is a collection of symptoms and signs associated with median neuropathy at the carpal tunnel. most cts is related to idiopathic compression of the median nerve as it travels through the wrist at the carpal tunnel. corticosteroid injection is an extensively used and accepted treatment in mild to moderate cts according to the guidelines of the american academy of orthopedic surgeons as corticosteroids reduce the inflammation and edema associated with cts. however, there is no guideline as to which corticosteroid has to be used as the standard treatment in cts. triamcinolone acetonide, a commonly used steroid for this indication, is a particulate steroid, which can cause permanent nerve injury if accidentally injected into the nerve. local ozone injection as a therapeutic option in some musculoskeletal conditions; ozone (o3) gas is a molecule consisting of three oxygen atoms in a dynamically unstable structure. ozone therapy has been utilized and studied for more than a century.

Eligibility criteria:
inclusion criteria: * age from 20 to 60 years. * both sexes. * patients with ultrasonographic evidence of mild-to-moderate carpal tunnel syndrome (cts). * inclusion criteria will include numbness and pain in the median nerve (mn) distribution persisting for minimum of 3 months , nerve conduction studies (ncs) consistent with carpal tunnel syndrome (cts) as per the american association of neuromuscular and electro diagnostic medicine (aanem) guidelines, and an median nerve (mn) cross-sectional area (csa)at the wrist \>12 mm2 suggesting mild-to-moderate cts forms. exclusion criteria: * patient refusal. * patients with severe symptoms and signs of cts as identified per the american association of neuromuscular and electro diagnostic medicine (aanem) guidelines,\[14\] as this is an indication for surgery, * patients who show improvement on medical treatment, * previous surgical or injectional cts treatment, * pregnancy ,co existence of brachial plexopathy, or thoracic outlet syndrome, polyneuropathy, radiculopathy and peripheral nerve lesion in upper limb. * severe cardiovascular disease * morbid obese patients (body mass index (bmi) of \>35 kg/m2) * infection at site of injection. * bleeding diathesis. * history of thyroid deficiency, uncontrolled diabetes mellitus , rheumatoid arthritis and history of glucose-6-phosphate dehydrogenase (g6pd) deficiency * history of ozone or dexmedetomidine allergy. * end stage renal and hepatic disease. * history of inflammatory joint , connective tissue disorders, , burns, any local tissue contractures and history of wrist trauma. * patients who will not consent to completing the visual analogue scale (vas) for pain or nerve conduction study before and after injection.
first relief treatment for peripheral neuropathy

Conditions: Peripheral Neuropathy

Summary: to prove the effectiveness of percutaneous electrical neuro-stimulation therapy for the treatment of conditions associated with peripheral neuropathy, in a double-blind environment.


Eligibility criteria:
inclusion criteria: * patients with neuropathy pain exclusion criteria: * patient with inbuilt pacemakers or any other devices which allows current into the body, pregnant ladies.

Keywords: first relief diebetes pheripheral neuropathy pain releif
anatomical resection vs. nonanatomical resection for colorectal liver metastases with gene mutation or right-sidedness

Conditions: Colorectal Carcinoma; Liver Metastases

Summary: in this study, colorectal cancer patients with initially resectable liver-only metastases, as prospectively confirmed by a local multidisciplinary team (mdt) according to predefined criteria, will be tested for ras and braf tumor mutation status. patients with gene mutant or right-sidedness will be randomised between anatomical resection (ar) or nonanatomical resection (nar). the primary end-point is the relapse-free survival.

this study is a prospective, single-center, randomized control trial. the major including criteria are (1) histologically confirmed colorectal cancer initially resectable liver-only metastases ; (2) patient has the opportunity to perform either anatomical resection (ar) or nonanatomical resection (nar) surgery; (3) the number of metastasis is 1-3; (4) kras/nras/braf mutation or right-sidedness. patients will be randomised between ar or nar. patients will be stratified for gene mutation and right-sidedness. based upon the segmental anatomy of the liver according to couinaud system, ar is defined as the resection of one or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination thereof. nar, also called as wedge resection, is defined as the resection of the tumor with a margin of normal parenchyma regardless of the hepatic anatomy. the primary end-point is the relapse-free survival. the secondary end-points are postoperative complication, postoperative mortality, hospital length of stay, and overall survival.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 and ≤ 75 years; 2. histological proof of colorectal adenocarcinoma; 3. resectable colorectal liver metastasis without detectable extrahepatic distant metastatic disease (determined by a local mdt); 4. suitable for anatomical or nonanatomical liver resection (determined by a local mdt); 5. number of metastasis is 1 to 3; 6. kras/nras/braf mutation or right-sidedness; 7. performance status (ecog) 0\~1; 8. adequate hematological function: neutrophils≥1.5 x109/l and platelet count≥100 x109/l; hb ≥9g/dl (within 1 week prior to randomization); 9. adequate liver and renal function: total bilirubin ≤2.0 mg/dl, serum transaminases ≤ 5x upper limit of normal(uln), and serum creatinine ≤ 1.5x uln and creatinine clearance ≥ 30 ml/min; 10. written informed consent. exclusion criteria: 1. previous systemic treatment for metastatic disease; 2. previous surgery for metastatic disease; 3. extrahepatic metastases; 4. unresectable primary tumor; 5. major cardiovascular events (myocardial infarction, severe/unstable angina, congestive heart failure, cva) within 12 months before randomisation; 6. second primary malignancy within the past 5 years; 7. acute or subacute intestinal obstruction; 8. drug or alcohol abuse; 9. no legal capacity or limited legal capacity; 10. pregnant or lactating women.
acute effect of high intensity interval exercise in patients with allergic rhinitis

Conditions: Allergic Rhinitis

Summary: the purpose of this study was to determine the acute effect of high intensity interval exercise on respiratory function and rhinitis symptoms in allergic rhinitis patients.

twelve patients with allergic rhinitis aged between 19 and 31 years who had a positive skin prick test to house dust mite (d. pteronyssinus). the experiment was a crossover design in which each participant was given two types of high-intensity interval training exercise (hit): hit 1:1 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternating with low intensity 50-55% of maximum heart rate for 1 minute) and hit 1:2 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternating with low intensity 50-55% of maximum heart rate for 2 minutes). rhinitis symptoms, nasal blood flow, peak nasal inspiratory flow, pulmonary functions, respiratory muscle strength, and fractional exhaled nitric oxide were measured before and immediately, 15 minutes, 30 minutes, 45 minutes, and 60 minutes after exercise for each exercise program.

Eligibility criteria:
inclusion criteria: * subjects had a clinical history of persistent rhinitis, and had positive skin prick test to house dust mite (d. pteronyssinus) * persistent allergic rhinitis * subjects with known asthma, chronic rhinosinusitis, lung cancer and emphysema diseases were excluded. * bmi 18.5 - 24.9 kg/m2 * subjects will ask to abstain from taking antihistamine for at least 5 days, leukotriene receptor antagonist for at least 1 week, and nasal steroids for at least 2 weeks prior to the start of the experiment. * subjects will ask to abstain from taking any form of dietary supplement during the experiment. * subjects had no exercise training program (not exercise regularly or not exercise for 30 minutes or more at least 3 times per week during the past 6 months) exclusion criteria: * accident that are unable to continue the research, such as accidental injury or illness, etc. * participants did not voluntarily participate.

Keywords: allergic rhinits acute exercise high intensity interval training rhinitis symptoms nasal blood flow
benefit of systematic proposition of nicotine substitution for patients undergoing surgery

Conditions: Smoking Cessation

Summary: smoking is associated with a higher rate of surgical complications. for example, in orthopedics, the risk of complications is 31% in smokers against 5% in non-smokers. the management of this addiction is recommended and particularly interesting in scheduled surgery, because it allows smoking cessation well before the procedure. however, for patients who cannot consider this smoking cessation, the mere information of the risk cannot be sufficient and a real strategy must be constructed and evaluated. currently, studies results indicate that a patient reducing the number of smoked cigarettes will unconsciously modify their smoking behaviour to obtain the usual nicotine level, this effect is called self-titration. conversely, nicotine replacement while continuing consumption could induce an improvement in smoking behaviour, therefore less intoxication which would be beneficial in terms of reduction of post-operative complications. this study seeks to assess the effectiveness of a systematic proposition of nicotine replacement therapy (nrt) in regular smokers. tobacco addiction specialists have demonstrated that intoxication and dependence are well correlated with the exhaled carbon monoxide (co) level, so this measurement will be used in addition to the patient's interview.


Eligibility criteria:
inclusion criteria: * patient who smokes at least one cigarette or cannabis joint per day, every day * patient received for nurse consultation at least 48 hours before surgery * patient planned to undergo surgery, with entry the day of surgery and 1 day of post-operative hospitalisation * patient in physical capacity and willing to undergo exhaled carbon monoxide measurement * for patients with one of the following chronic diseases: diabetes, chronic obstructive pulmonary disease, glucose intolerance, hemolytic anemia, asthma and dilation of the bronchi, these diseases must be stable * signature of the specific study informed consent * patient affiliated or beneficiary of social security system exclusion criteria: * inability to submit to study follow-up for geographic, social or psychological reasons * patient already included in an interventional clinical research protocol * patients protected by french law from clinical research inclusion (pregnant, in labour, breastfeeding, legally protected, under judiciary or administrative liberty deprivation) * patient using nicotine substitutes before the nurse consultation * alcohol consumption six hours before the exhaled carbon monoxide measurement

Keywords: postoperative complication nicotine replacement therapy exhaled carbon monoxide level